Denovo Biopharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Denovo Biopharma - overview
Established
2012
Location
Hangzhou, Zhejiang, China
Primary Industry
Biotechnology
About
Established in 2012 and based in Beijing, Denovo Biopharma is a biotechnology company that uses the technology to develop drugs. The company is headquartered in Hangzhou, with a clinical operations center in Beijing and a subsidiary in the United States. Dr. Wen Luo, the company's Chairman and Managing Director, has over 20 years of experience in the biopharmaceutical industry, having worked at Ligand.
In May 2024, it raised a strategic funding for approximately USD 12 million. The company’s main business is the development of antitumor drugs. The company’s self-developed pipeline such as DB102 for glioma, DB106 for acute myeloid leukemia, DB109 for Alzheimer's disease, and DB103 for schizophrenia. The company generates revenues by providing antitumor and drugs for the treatment of the central nervous system.
The company will use the strategic funding to develop DB107, a gene therapy for brain tumors, which includes a clinical Phase 1/2 trial for glioblastoma (GBM).
Current Investors
Yuexiu Industrial Investment Funds Management, Qingdao Goldstone Haorui Investment, Zhejiang Xianju Pharmaceutical Co.,Ltd
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.denovobiopharma.com
Verticals
Manufacturing
Company Stage
Series D
Total Amount Raised
Subscriber access only
Denovo Biopharma - financials
| Fiscal Year Ended | Dec 31, 2016 |
|---|---|
| Revenue (USD) | - |
| % Revenue Growth (YoY) | - |
| EBITDA (USD) | - |
| Operating Income (USD) | - |
| Operating Margin | - |
| % EBITDA Margin | - |
| NET Income (USD) | - |
| % Net Margin | - |
Denovo Biopharma - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unspecified Round | Completed | Denovo Biopharma | - | ||||||||
| Series D | Completed | Denovo Biopharma | - | ||||||||
| Series C | Completed | Denovo Biopharma | - | ||||||||
| Series B | Completed | Denovo Biopharma | - | ||||||||
| Series B | Completed | Denovo Biopharma | - |
Displaying 1 - 5 of 6
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.